Celgene
High Dose Chemotherapy(Celgene)은 FRα 표적 ADC로, Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 29% (ClinicalTrials.gov NCT01182415). 차별점: uniquely underserved population.
FRα
Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
Recruiting
bispecific antibodies, and BV combined with ICE, ultimately achieving
vedotin (BV) maintenance therapy improves patie
uniquely underserved population
targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen
antibody-dependent cellular cytotoxicity
biomarkers are critical to predict which patients will require treatment escalation
resistance to neoadjuvant immunochemotherapy in resectable NSCLC
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Celgene
High Dose Chemotherapy(Celgene)은 FRα 표적 ADC로, Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 29% (ClinicalTrials.gov NCT01182415). 차별점: uniquely underserved population.
FRα
Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
Recruiting
bispecific antibodies, and BV combined with ICE, ultimately achieving
vedotin (BV) maintenance therapy improves patie
uniquely underserved population
targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen
antibody-dependent cellular cytotoxicity
biomarkers are critical to predict which patients will require treatment escalation
resistance to neoadjuvant immunochemotherapy in resectable NSCLC
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.